WO2009117987A3 - Verwendung von boswelliasäuren und synthetischen boswelliasäurederivaten zur hemmung der mikrosomalen prostaglandin e2 synthase und des cathepsin g - Google Patents

Verwendung von boswelliasäuren und synthetischen boswelliasäurederivaten zur hemmung der mikrosomalen prostaglandin e2 synthase und des cathepsin g Download PDF

Info

Publication number
WO2009117987A3
WO2009117987A3 PCT/DE2009/000385 DE2009000385W WO2009117987A3 WO 2009117987 A3 WO2009117987 A3 WO 2009117987A3 DE 2009000385 W DE2009000385 W DE 2009000385W WO 2009117987 A3 WO2009117987 A3 WO 2009117987A3
Authority
WO
WIPO (PCT)
Prior art keywords
boswellia
acid derivatives
cathepsin
synthetic
synthase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DE2009/000385
Other languages
English (en)
French (fr)
Other versions
WO2009117987A2 (de
Inventor
Oliver Werz
Joachim-Friedrich Kapp
Roland Martin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MEDEON PHARMACEUTICALS GmbH
Eberhard Karls Universitaet Tuebingen
Original Assignee
MEDEON PHARMACEUTICALS GmbH
Eberhard Karls Universitaet Tuebingen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102008015607A external-priority patent/DE102008015607A1/de
Priority claimed from DE102008017496A external-priority patent/DE102008017496A1/de
Application filed by MEDEON PHARMACEUTICALS GmbH, Eberhard Karls Universitaet Tuebingen filed Critical MEDEON PHARMACEUTICALS GmbH
Publication of WO2009117987A2 publication Critical patent/WO2009117987A2/de
Publication of WO2009117987A3 publication Critical patent/WO2009117987A3/de
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Die vorliegende Erfindung betrifft neue Boswelliasäurederivate. Die vorliegende Erfindung betrifft ferner die Verwendung von Zubereitungen mit Boswelliasäuren bzw. synthetischer Derivate insbesondere Boswelliasäure-Derivate, die an der C3-OH-Funktion verestert oder verethert sind, zur Hemmung der induzierbaren mikrosomalen Prostaglandin E2 Synthase-1 und/oder zur Hemmung des Cathepsin G. Ferner betrifft die Erfindung Verwendung von Boswelliasäuren bzw. synthetischer Derivate zur Herstellung eines Arzneimittels zur Behandlung von PGE2- und/oder Cathepsin G-vermittelter krankhafter Zustände.
PCT/DE2009/000385 2008-03-26 2009-03-25 Verwendung von boswelliasäuren und synthetischen boswelliasäurederivaten zur hemmung der mikrosomalen prostaglandin e2 synthase und des cathepsin g Ceased WO2009117987A2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE102008015607A DE102008015607A1 (de) 2008-03-26 2008-03-26 Verwendung von Boswelliasäuren und synthetischen Boswelliasäurederivaten zur Hemmung der mikrosomalen Prostaglandin E2 Synthase und des Cathepsin G
DE102008015607.8 2008-03-26
DE102008017496.3 2008-04-04
DE102008017496A DE102008017496A1 (de) 2008-04-04 2008-04-04 Verwendung von Boswelliasäure und Boswelliasäurederivaten zur Herstellung von Arzneimitteln zur Therapie von Multipler Sklerose

Publications (2)

Publication Number Publication Date
WO2009117987A2 WO2009117987A2 (de) 2009-10-01
WO2009117987A3 true WO2009117987A3 (de) 2009-12-03

Family

ID=40942410

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2009/000385 Ceased WO2009117987A2 (de) 2008-03-26 2009-03-25 Verwendung von boswelliasäuren und synthetischen boswelliasäurederivaten zur hemmung der mikrosomalen prostaglandin e2 synthase und des cathepsin g

Country Status (1)

Country Link
WO (1) WO2009117987A2 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020263830A1 (en) 2019-06-25 2020-12-30 Gilead Sciences, Inc. Flt3l-fc fusion proteins and methods of use
ES2973832T3 (es) 2019-10-18 2024-06-24 Forty Seven Inc Terapias combinadas para el tratamiento de síndromes mielodisplásicos y leucemia mieloide aguda
JP2022552748A (ja) 2019-10-31 2022-12-19 フォーティ セブン， インコーポレイテッド 抗ｃｄ４７及び抗ｃｄ２０による血液癌の治療
TWI778443B (zh) 2019-11-12 2022-09-21 美商基利科學股份有限公司 Mcl1抑制劑
IL294032A (en) 2019-12-24 2022-08-01 Carna Biosciences Inc Compounds that regulate diacylglycerol kinase
TWI890283B (zh) 2020-02-14 2025-07-11 美商基利科學股份有限公司 結合ccr8之抗體及融合蛋白及其用途
IL297327B2 (en) 2020-05-01 2026-01-01 Gilead Sciences Inc 4,2-dioxopyrimidine compounds CD73 inhibitors
CN112225775A (zh) * 2020-10-28 2021-01-15 籍建亚 一种抗菌消炎熊果酸衍生物及其制备方法
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
WO2022245671A1 (en) 2021-05-18 2022-11-24 Gilead Sciences, Inc. Methods of using flt3l-fc fusion proteins
JP7686091B2 (ja) 2021-06-23 2025-05-30 ギリアード サイエンシーズ， インコーポレイテッド ジアシルグリセロールキナーゼ調節化合物
JP7651018B2 (ja) 2021-06-23 2025-03-25 ギリアード サイエンシーズ， インコーポレイテッド ジアシルグリセロールキナーゼ調節化合物
MX2023014762A (es) 2021-06-23 2024-01-15 Gilead Sciences Inc Compuestos moduladores de diacilglicerol quinasa.
AU2022299051B2 (en) 2021-06-23 2025-03-13 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
AU2022375782B2 (en) 2021-10-28 2026-02-26 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
JP7787991B2 (ja) 2021-10-29 2025-12-17 ギリアード サイエンシーズ， インコーポレイテッド Ｃｄ７３化合物
US12122764B2 (en) 2021-12-22 2024-10-22 Gilead Sciences, Inc. IKAROS zinc finger family degraders and uses thereof
KR20240123836A (ko) 2021-12-22 2024-08-14 길리애드 사이언시즈, 인코포레이티드 이카로스 아연 핑거 패밀리 분해제 및 이의 용도
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
WO2023178181A1 (en) 2022-03-17 2023-09-21 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
KR20240165995A (ko) 2022-03-24 2024-11-25 길리애드 사이언시즈, 인코포레이티드 Trop-2 발현 암의 치료를 위한 병용요법
TWI876305B (zh) 2022-04-05 2025-03-11 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
CR20240451A (es) 2022-04-21 2024-12-04 Gilead Sciences Inc Compuestos de modulación de kras g12d
KR20250028371A (ko) 2022-07-01 2025-02-28 길리애드 사이언시즈, 인코포레이티드 Cd73 화합물
WO2024064668A1 (en) 2022-09-21 2024-03-28 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
AU2023409398A1 (en) 2022-12-22 2025-06-05 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
AU2024252725A1 (en) 2023-04-11 2025-11-06 Gilead Sciences, Inc. Kras modulating compounds
CR20250446A (es) 2023-04-21 2025-12-02 Gilead Sciences Inc Inhibidores de prmt5 y usos de los mismos
AU2024306338A1 (en) 2023-06-30 2026-01-08 Gilead Sciences, Inc. Kras modulating compounds
CN121620513A (zh) 2023-07-26 2026-03-06 吉利德科学公司 Parp7抑制剂
KR20260046403A (ko) 2023-07-26 2026-04-07 길리애드 사이언시즈, 인코포레이티드 Parp7 저해제
US20250101042A1 (en) 2023-09-08 2025-03-27 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250154172A1 (en) 2023-11-03 2025-05-15 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025245003A1 (en) 2024-05-21 2025-11-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
US20260098049A1 (en) 2024-08-12 2026-04-09 Gilead Sciences, Inc. Kras modulating compounds

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04288095A (ja) * 1991-01-22 1992-10-13 Tsumura & Co 補体活性抑制剤
EP0755940A1 (de) * 1995-04-13 1997-01-29 Council of Scientific and Industrial Research Boswellsäure Zusammensetzungen und die Herstellung davon
WO2003099302A1 (en) * 2002-05-24 2003-12-04 Turispharma S.R.L. A terpene-based composition of substances, a method for its preparation and a method for its dispersal into the atmosphere
CN1615888A (zh) * 2004-08-31 2005-05-18 凌沛学 一种药物组合物及其用途
WO2005123649A1 (en) * 2004-06-18 2005-12-29 Ganga Raju Gokaraju NOVEL ANALOGS OF 3-O-ACETYL-11-KETO-β-BOSWELLIC ACID
WO2008058514A1 (de) * 2006-11-14 2008-05-22 Eberhard Karls Universität Tübingen Zubereitungen enthaltend boswelliasäuren zur hemmung der prostaglandin e2 synthese

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04288095A (ja) * 1991-01-22 1992-10-13 Tsumura & Co 補体活性抑制剤
EP0755940A1 (de) * 1995-04-13 1997-01-29 Council of Scientific and Industrial Research Boswellsäure Zusammensetzungen und die Herstellung davon
WO2003099302A1 (en) * 2002-05-24 2003-12-04 Turispharma S.R.L. A terpene-based composition of substances, a method for its preparation and a method for its dispersal into the atmosphere
WO2005123649A1 (en) * 2004-06-18 2005-12-29 Ganga Raju Gokaraju NOVEL ANALOGS OF 3-O-ACETYL-11-KETO-β-BOSWELLIC ACID
CN1615888A (zh) * 2004-08-31 2005-05-18 凌沛学 一种药物组合物及其用途
WO2008058514A1 (de) * 2006-11-14 2008-05-22 Eberhard Karls Universität Tübingen Zubereitungen enthaltend boswelliasäuren zur hemmung der prostaglandin e2 synthese

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; HAYASHI, KOJI ET AL: "Complement inhibitors containing .beta.-boswellic acid (derivatives)", XP002541974, retrieved from STN Database accession no. 1993:109686 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; LING, PEIXUE ET AL: "Manufacture of medicine composition for treating rheumatic arthritis and rheumatoid arthritis", XP002541975, retrieved from STN Database accession no. 2005:1257930 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; TANEJA, SUBHASH CHANDRA ET AL: "A process for the preparation of O-acylates of .beta.-boswellic acids", XP002541976, retrieved from STN Database accession no. 2003:971411 *
MAHAJAN, BABITA ET AL: "Two triterpenoids from Boswellia serrata gum resin", PHYTOCHEMISTRY , 39(2), 453-5 CODEN: PYTCAS; ISSN: 0031-9422, 1995, XP002541973 *

Also Published As

Publication number Publication date
WO2009117987A2 (de) 2009-10-01

Similar Documents

Publication Publication Date Title
WO2009117987A3 (de) Verwendung von boswelliasäuren und synthetischen boswelliasäurederivaten zur hemmung der mikrosomalen prostaglandin e2 synthase und des cathepsin g
WO2007127377A3 (en) Combinations comprising omega-3 fatty acid compounds for the treatment of cardiovascular disease
WO2010042163A3 (en) Quinoline compounds as inhibitors of angiogenesis, human methionine aminopeptidase, and sirt1, and methods of treating disorders
WO2010078512A3 (en) Production of substituted phenylene aromatic diesters
WO2011139702A3 (en) Modified nucleosides and oligomeric compounds prepared therefrom
WO2012076466A3 (de) Substituierte 1-benzylcycloalkylcarbonsäuren und ihre verwendung
WO2008070268A3 (en) Pharmaceutical compositions
WO2008070129A3 (en) Compositions and methods for the treatment of inflammatory disease
WO2010127152A3 (en) Compounds and compositions as microsomal prostaglandin e synthase-1 inhibitors
WO2011141909A3 (en) Lipoic acid and nitroxide derivatives and uses thereof
WO2009100183A3 (en) Variant buttiauxela sp. phytases having altered properties
WO2010150211A3 (en) Use of derivatives of indoles for the treatment of cancer
WO2009149921A8 (en) Inhibition of hrp-3 using modified oligonucleotides
WO2007095383A3 (en) Prodrugs
WO2009124962A3 (en) Sulfonamides
WO2009040113A3 (en) C5a BINDING NUCLEIC ACIDS
WO2012075015A3 (en) Oral metronidazole pharmaceutical compositions
WO2009040314A3 (de) Neue heteroarylsubstituierte acetonderivate, geeignet zur hemmung der phospholipase a2
WO2010062506A3 (en) Decahydro-1h-indenoquinolinone and decahydro-3h-cyclopentaphenanthridinone cyp17 inhibitors
WO2011130426A3 (en) Compositions and methods for treatment of melanoma
WO2010027844A3 (en) Distal section for monorail catheter
WO2011073370A3 (fr) Utilisation du 2,3-dihydroxypropyl dodécanoate pour le traitement de la séborrhée
MX339361B (es) Derivados de alternano.
WO2010015656A3 (en) Alkoxypyrazoles and the process for their preparation
WO2010077310A3 (en) Amide derivatives of ethacrynic acid

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09723945

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 09723945

Country of ref document: EP

Kind code of ref document: A2